SecBot SecBot

AMRN

AMARIN CORP PLCUK
Nasdaq· Pharmaceutical Preparations· Inc. X0· CIK 0000897448 Biotech & Drug Discovery
$11.38 −0.29 (−2.49%)
Nov 13 4:00 PM ET · prev $11.67
Market cap
$240.8M
Micro cap
Median target
$13.00
+14% · range $13.00–13.00
1 year
−29.1%
from $16.04 · Nov 17
30 days
−1.3%
from $11.53
52-week range
$11.32–16.98
−33% from high · low Oct 16
Avg volume 20D
77.6K
shares / day
Short interest
537.9K
≈2.6% of shares · +1.0%
Days to cover
7.6
at average volume
Insider net
$0
no open-market trades · since Jan 31
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 0 bearish · 0 bullish · 1 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/4

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Jan 31. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q3 2026: 4 added (0 new), 6 trimmed or exited.

  • Short sellersSTEADY

    Short interest +1.0% to 537.9K shares. 7.6 days to cover, ≈2.6% of shares.

  • TrendRANGE

    9% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
JANE STREET GROUP, LLCTRIM24,809$322.5K
Steward Partners Investment Advisory, LLCADD11,479$149.2K
UBS Group AGTRIM6,272$81.5K
BlackRock, Inc.TRIM423$5.5K
CITIGROUP INCNEAR_EXIT2$26.00
MILLENNIUM MANAGEMENT LLCTRIM115,808$1.8M
RENAISSANCE TECHNOLOGIES LLCDOUBLED48,369$771.0K
BlackRock, Inc.TRIM858$13.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Jun 2025
12-month targets · 1 analysts

Price is below the lowest target. Median implies +14%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Jun 25, 2025Goldman Sachs
MAINTAIN
MAINTAINSell
Apr 17, 2025Goldman Sachs
MAINTAIN
MAINTAINSell
Jun 20, 2024Cantor Fitzgerald
REITERATE
REITERATEOverweight
Jun 18, 2024Cantor Fitzgerald
REITERATE
REITERATEOverweight
Oct 25, 2023Jefferies
DOWNGRADE
DOWNGRADEHold
Jul 20, 2023Goldman Sachs
MAINTAIN
MAINTAINSell

Insider ledger

Form 4
$0
open-market buys or sells · since Jan 31
DateInsiderTypeValue
Aug 1, 2026
Fishman Peter L.
SVP, CFO
Aug 1, 2026
EXERCISE313 sh
Aug 1, 2026
Fishman Peter L.
SVP, CFO
Aug 1, 2026
TAX W/H$2.2K
Aug 1, 2026
Fishman Peter L.
SVP, CFO
Aug 1, 2026
AWARD313 sh
Jul 1, 2026
Provoost Jonathan
EVP, Chief Legal Officer
Jul 1, 2026
AWARD3,688 sh
Jul 1, 2026
Provoost Jonathan
EVP, Chief Legal Officer
Jul 1, 2026
TAX W/H$20.1K
Jul 1, 2026
Ketchum Steven B
EVP, Chief Scientific Officer
Jul 1, 2026
AWARD3,688 sh
Jul 1, 2026
Ketchum Steven B
EVP, Chief Scientific Officer
Jul 1, 2026
TAX W/H$30.1K
Jul 1, 2026
Provoost Jonathan
EVP, Chief Legal Officer
Jul 1, 2026
EXERCISE3,688 sh

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current QNoneNoneNo data$50.0M
Next QNoneNoneNo data$0.00
Current FYNoneNoneNo data$183.4M
Next FYNoneNoneNo data$189.0M

Short side

FINRA· Oct 30, 2026
537,876
shares short
+1.0%
vs prior settlement
7.6
days to cover
≈2.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Oct 28, 2026 SEC
Amarin reported Q3 2026 GAAP net income of $0.2M, its first profitable quarter in over two years, versus a net loss of…
8-K · Impact 5/10
Oct 28, 2026 SEC
Amarin reported Q3 2026 net income of $0.2M, its first profitable quarter in over two years, on revenue of $39.6M…
PRESS-RELEASE · Impact 5/10
Oct 28, 2026 Earnings
Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income
DUBLIN and BRIDGEWATER, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN
Oct 25, 2026 Press
Amarin announced Phase 3 EMT2 trial results for VAZKEPA/VASCEPA (icosapent ethyl) in colorectal cancer liver…
Impact 6/10
Sep 30, 2026 Inst.
JANE STREET GROUP, LLC · TRIM
24,809 shares ($322.5K)
Sep 30, 2026 Inst.
Steward Partners Investment Advisory, · ADD
11,479 shares ($149.2K)
Aug 28, 2026 Press
Amarin announced a post-hoc analysis from the REDUCE-IT trial at ESC 2026, showing that highly adherent patients on…
Impact 4/10
Aug 1, 2026 Insider
Fishman Peter L. acquired via exercise 313 shares
SVP, CFO
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

5 filings · 3 press releases · 0 bullish · 2 bearish · 3 neutral
All AMRN filing & press-release reports (8)